Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
You may also be interested in...
The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.
Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.